Allergan Inc (AGN) 190.06 $AGN
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.18 (-0.65), AGN: 190.06 (+0.62), ACT: 242.74 (-0.47), BMY: 58.19 (-0.79)
Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks
at The Street - Fri Oct 31, 9:54AM CDT
Remember these franchises and who captains them.
AGN: 190.06 (+0.62), MMM: 153.77 (+1.67), CMG: 638.00 (-1.68), BMY: 58.19 (-0.79)
AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)
Global Hyaluronic Acid (HA) (Dermal Fillers, Osteoarthritis, Ophthalmic & VUR) Market Outlook, 2018
M2 - Fri Oct 31, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cg7ml7/global_hyaluronic) has announced the addition of the "Global Hyaluronic Acid (HA) Market 2014-2018" report to their offering. The Global HA Market will grow at a CAGR of 9.14% over the period 2013-2018 Hyaluronic acid (HA) or glass acid is a naturally occurring non-sulfated glycosaminoglycan. It is present in the human body in the joints, eye cavity, and internal defense systems. It functions as a nutrient carrier, along with helping the tissues in retaining water. It is an integral part of the extracellular matrix and is found in the coverings around chondrocytes. HA is produced commercially by various processes, including extraction from animal tissues, bacterial production, and in-vitro production. Its major medical applications are viscosupplementation for osteoarthritis, ophthalmic, VUR, and dermal fillers. HA is commercially available in the form of single-injection cycle HA products, three-injection cycle HA products, and five-injection cycle HA products. The shift in consumer preference for premium priced single-injection cycle HA products over low-priced five-injection cycle HA products owing to the shorter treatment regimen is the major positive trend being witnessed in this market. The shorter regimens are more convenient as patients want to reduce the number of steps in the treatment owing to the side effects and pain felt after each injection. According to the report, the growth in the geriatric population globally is one of the major drivers in the market. HA is used extensively in the Medical sector for treating osteoarthritic patients through viscosupplementation. As osteoarthritis is caused by the deterioration of body's ability to repair its cartilage with increasing age, the Global HA market is expected to experience strong growth as a result of the increasing geriatric population. Further, the report states that the threat of substitution by utilizing an alternative method for the treatment of osteoarthritis is the major obstacle hindering the growth of this market. There has been an increase in the number of substitutes for HA viscosupplementation for the treatment of osteoarthritis in recent years including cyclooxygenase-2 inhibitors and joint arthroplasty. The development and popularity of new procedures is making it difficult for manufacturers in the market to maintain their market share. The Global HA market can be divided on the basis of application into the following segments: - Dermal Fillers - Osteoarthritis - Ophthalmic - VUR Key Vendors - Allergan - Ferring Pharmaceuticals - Fidia Farmaceutici - Sanofi - Seikagaku For more information visit http://www.researchandmarkets.com/research/cg...hyaluronic
AGN: 190.06 (+0.62)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 190.06 (+0.62), NVO: 45.18 (-1.03), ABBV: 63.46 (+2.28), SNY: 46.24 (+0.54)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)
Shares of AGN Up 11.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 30, 9:25AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 11.79% as of today's recent price of $186.80.
AGN: 190.06 (+0.62)
Botulinum Toxin - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qw6vx2/botulinum_toxin) has announced the addition of the "Botulinum Toxin - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: - Cosmetic Applications - Therapeutic Applications The report profiles 19 companies including many key and niche players such as: - Allergan, Inc. - Ipsen Group - Medy-Tox Incorporated - Mentor Corporation - Merz Pharma GmbH & Co. KGaA - Metabiologics, Inc. - Revance Therapeutics, Inc. - US WorldMeds Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends & Issues 4. Product/Industry Dynamics 5. Product Overview 6. Research Breakthroughs 7. Product Introductions/Approvals 8. Recent Industry Activity 9. Focus On Select Global Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 19 (including Divisions/Subsidiaries - 23) - The United States (9) - Japan (2) - Europe (6) - -France (1) - - Germany (1) - - The United Kingdom (3) - - Rest of Europe (1) - Asia-Pacific (Excluding Japan) (6) For more information visit http://www.researchandmarkets.com/research/qw...inum_toxin
AGN: 190.06 (+0.62), RVNC: 20.16 (+0.54)
eVivite.com Continues to Sell VIVITÉ(R) Products After Allergan Announces Its Discontinuation
PRWeb - Thu Oct 30, 2:01AM CDT
After Allergan's announcement that they will be discontinuing their VIVITÉ(R) skin care product line, online supplier eVivite.com announced their plans to resume sales as long as products are available. As of March 2014 Allergen had already halted production of the products, and they informed retailers that they would only be distributing what had already been produced. The final shipments to suppliers are expected to occur sometime in June.
AGN: 190.06 (+0.62)
San Marcos Dentist, Jeffrey Allred, Certified by Allergan to Provide Botox to Patients Having Dental Problems
PRWeb - Wed Oct 29, 2:11PM CDT
Jeffrey Allred DDS at Allred Dental in San Marcos, CA is now providing therapeutic Botox injections. Botox till recently was known to be used mainly for cosmetic purposes, but now it is used in dentistry as well.
AGN: 190.06 (+0.62)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 190.06 (+0.62), ESRX: 76.82 (+1.28), CAH: 78.48 (+0.29), UNH: 95.01 (+1.13), CRL: 63.16 (+0.35)
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:04PM CDT
Novartis reported core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
AGN: 190.06 (+0.62), LLY: 66.33 (-0.47), GSK: 45.49 (+0.35), NVS: 92.69 (+0.74)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.92 (+0.63), VRX: 133.04 (+1.53), ACT: 242.74 (-0.47), AMGN: 162.18 (+0.60), TKMR: 16.68 (-0.26), GSK: 45.49 (+0.35), AGN: 190.06 (+0.62), JNJ: 107.78 (+0.74), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), INFI: 13.62 (-0.19), ABBV: 63.46 (+2.28), KPTI: 41.08 (+1.03)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 190.06 (+0.62), MCK: 203.41 (-0.07), CAH: 78.48 (+0.29), CRL: 63.16 (+0.35)
Allergan Canada Launches a 3D JUVEDERM(R) Visualization iPad App Powered by ModiFace
Marketwired - Wed Oct 29, 8:02AM CDT
Allergan Canada, in partnership with ModiFace Inc., is delighted to announce the launch of the Juvederm(R) Visualizer 3D iPad application. For the first time, users can create a 3D image of the potential results of Juvederm(R) facial filler showing all angles of their face. This new application enables you to simulate the effects of Juvederm(R) facial filler by creating a 3D image of your face that can be rotated and viewed from all angles. You can then apply over 10 Juvederm(R) treatment effects such as smoothing laugh lines and enhancing cheeks and lips.
AGN: 190.06 (+0.62)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 190.06 (+0.62), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:10PM CDT
Pfizer's (PFE) third quarter earnings and revenues were better-than-expected despite the presence of generic pressure.
AGN: 190.06 (+0.62), BIIB: 321.08 (+0.08), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28)
Allergan (AGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Oct 28, 1:44PM CDT
The following Allergan (AGN) conference call took place on October 27, 2014, 09:00 AM ET. This is a transcript of that earnings call:
AGN: 190.06 (+0.62)
Stock Market News for October 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 9:10AM CDT
Benchmarks were little changed on Monday as investors took a breather following last week’s sharp gains
MU: 33.09 (+1.27), VRX: 133.04 (+1.53), NBR: 17.85 (+0.35), HAL: 55.14 (+1.22), XOM: 96.71 (+2.26), BRCD: 10.73 (+0.24), SLB: 98.66 (+1.04), AGN: 190.06 (+0.62), CHK: 22.18 (+0.83), MRK: 57.94 (+0.63), EOG: 95.05 (+2.83), DD: 69.15 (+1.49), PX: 125.99 (+3.32), CVX: 119.95 (+2.75), VZ: 50.25 (+0.35), DOW: 49.40 (+1.15), ECL: 111.23 (+2.88)
Bristol-Myers Squibb Up on Positive Opdivo Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:46PM CDT
Bristol-Myers Squibb Company announced encouraging data from the phase II CheckMate - 063 study on immuno-oncology drug Opdivo.
MNK: 92.18 (-0.65), AGN: 190.06 (+0.62), ACT: 242.74 (-0.47), BMY: 58.19 (-0.79)
Cramer on the Stock Market: Find the Best of Best-of-Breed Stocks
at The Street - Fri Oct 31, 9:54AM CDT
Remember these franchises and who captains them.
AGN: 190.06 (+0.62), MMM: 153.77 (+1.67), CMG: 638.00 (-1.68), BMY: 58.19 (-0.79)
AbbVie Q3 Earnings Top on Humira Sales, Boosts Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 9:33AM CDT
AbbVie (ABBV) raised it outlook for 2014 - the new guidance surpassed expectations.
AGN: 190.06 (+0.62), SHPG: 199.80 (+0.38), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79)
Global Hyaluronic Acid (HA) (Dermal Fillers, Osteoarthritis, Ophthalmic & VUR) Market Outlook, 2018
M2 - Fri Oct 31, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cg7ml7/global_hyaluronic) has announced the addition of the "Global Hyaluronic Acid (HA) Market 2014-2018" report to their offering. The Global HA Market will grow at a CAGR of 9.14% over the period 2013-2018 Hyaluronic acid (HA) or glass acid is a naturally occurring non-sulfated glycosaminoglycan. It is present in the human body in the joints, eye cavity, and internal defense systems. It functions as a nutrient carrier, along with helping the tissues in retaining water. It is an integral part of the extracellular matrix and is found in the coverings around chondrocytes. HA is produced commercially by various processes, including extraction from animal tissues, bacterial production, and in-vitro production. Its major medical applications are viscosupplementation for osteoarthritis, ophthalmic, VUR, and dermal fillers. HA is commercially available in the form of single-injection cycle HA products, three-injection cycle HA products, and five-injection cycle HA products. The shift in consumer preference for premium priced single-injection cycle HA products over low-priced five-injection cycle HA products owing to the shorter treatment regimen is the major positive trend being witnessed in this market. The shorter regimens are more convenient as patients want to reduce the number of steps in the treatment owing to the side effects and pain felt after each injection. According to the report, the growth in the geriatric population globally is one of the major drivers in the market. HA is used extensively in the Medical sector for treating osteoarthritic patients through viscosupplementation. As osteoarthritis is caused by the deterioration of body's ability to repair its cartilage with increasing age, the Global HA market is expected to experience strong growth as a result of the increasing geriatric population. Further, the report states that the threat of substitution by utilizing an alternative method for the treatment of osteoarthritis is the major obstacle hindering the growth of this market. There has been an increase in the number of substitutes for HA viscosupplementation for the treatment of osteoarthritis in recent years including cyclooxygenase-2 inhibitors and joint arthroplasty. The development and popularity of new procedures is making it difficult for manufacturers in the market to maintain their market share. The Global HA market can be divided on the basis of application into the following segments: - Dermal Fillers - Osteoarthritis - Ophthalmic - VUR Key Vendors - Allergan - Ferring Pharmaceuticals - Fidia Farmaceutici - Sanofi - Seikagaku For more information visit http://www.researchandmarkets.com/research/cg...hyaluronic
AGN: 190.06 (+0.62)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Sanofi Beats on Q3 Earnings but Lantus Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:45PM CDT
Sanofi reported third-quarter 2014 business earnings of 97 cents per ADS, 3 cents above the Zacks Consensus Estimate.
AGN: 190.06 (+0.62), NVO: 45.18 (-1.03), ABBV: 63.46 (+2.28), SNY: 46.24 (+0.54)
Charles River (CRL) Beats on Q3 Earnings, Guidance Upped - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 11:30AM CDT
Charles River Laboratories (CRL) reported third-quarter 2014 earnings (excluding special items) of 86 cents per share.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), BMY: 58.19 (-0.79), CRL: 63.16 (+0.35)
Shares of AGN Up 11.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Oct 30, 9:25AM CDT
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 2 months, Allergan has returned 11.79% as of today's recent price of $186.80.
AGN: 190.06 (+0.62)
Botulinum Toxin - Global Strategic Business Report 2014-2020
M2 - Thu Oct 30, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qw6vx2/botulinum_toxin) has announced the addition of the "Botulinum Toxin - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Segments: - Cosmetic Applications - Therapeutic Applications The report profiles 19 companies including many key and niche players such as: - Allergan, Inc. - Ipsen Group - Medy-Tox Incorporated - Mentor Corporation - Merz Pharma GmbH & Co. KGaA - Metabiologics, Inc. - Revance Therapeutics, Inc. - US WorldMeds Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competition 3. Market Trends & Issues 4. Product/Industry Dynamics 5. Product Overview 6. Research Breakthroughs 7. Product Introductions/Approvals 8. Recent Industry Activity 9. Focus On Select Global Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Rest Of World IV. Competitive Landscape Total Companies Profiled: 19 (including Divisions/Subsidiaries - 23) - The United States (9) - Japan (2) - Europe (6) - -France (1) - - Germany (1) - - The United Kingdom (3) - - Rest of Europe (1) - Asia-Pacific (Excluding Japan) (6) For more information visit http://www.researchandmarkets.com/research/qw...inum_toxin
AGN: 190.06 (+0.62), RVNC: 20.16 (+0.54)
eVivite.com Continues to Sell VIVITÉ(R) Products After Allergan Announces Its Discontinuation
PRWeb - Thu Oct 30, 2:01AM CDT
After Allergan's announcement that they will be discontinuing their VIVITÉ(R) skin care product line, online supplier eVivite.com announced their plans to resume sales as long as products are available. As of March 2014 Allergen had already halted production of the products, and they informed retailers that they would only be distributing what had already been produced. The final shipments to suppliers are expected to occur sometime in June.
AGN: 190.06 (+0.62)
San Marcos Dentist, Jeffrey Allred, Certified by Allergan to Provide Botox to Patients Having Dental Problems
PRWeb - Wed Oct 29, 2:11PM CDT
Jeffrey Allred DDS at Allred Dental in San Marcos, CA is now providing therapeutic Botox injections. Botox till recently was known to be used mainly for cosmetic purposes, but now it is used in dentistry as well.
AGN: 190.06 (+0.62)
Express Scripts Reports In-Line Q3 Earnings, Narrows View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:26PM CDT
Express Scripts Holding Company posted third-quarter 2014 earnings per share (excluding special items) of $1.29, in line with the Zacks Consensus Estimate.
AGN: 190.06 (+0.62), ESRX: 76.82 (+1.28), CAH: 78.48 (+0.29), UNH: 95.01 (+1.13), CRL: 63.16 (+0.35)
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:04PM CDT
Novartis reported core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
AGN: 190.06 (+0.62), LLY: 66.33 (-0.47), GSK: 45.49 (+0.35), NVS: 92.69 (+0.74)
3 Health Care Picks To Beat Earnings - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 11:09AM CDT
These stocks are well positioned in today's market environment.
ENDP: 66.92 (+0.63), VRX: 133.04 (+1.53), ACT: 242.74 (-0.47), AMGN: 162.18 (+0.60), TKMR: 16.68 (-0.26), GSK: 45.49 (+0.35), AGN: 190.06 (+0.62), JNJ: 107.78 (+0.74), SHPG: 199.80 (+0.38), MRK: 57.94 (+0.63), INFI: 13.62 (-0.19), ABBV: 63.46 (+2.28), KPTI: 41.08 (+1.03)
McKesson Beats on Q2 Earnings, Revenues; Keeps Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 10:14AM CDT
McKesson Corporation (MCK) reported fiscal second-quarter 2015 (ended Sep 30, 2014) earnings of $2.79 per share, comfortably beating the Zacks Consensus Estimate of $2.74
AGN: 190.06 (+0.62), MCK: 203.41 (-0.07), CAH: 78.48 (+0.29), CRL: 63.16 (+0.35)
Allergan Canada Launches a 3D JUVEDERM(R) Visualization iPad App Powered by ModiFace
Marketwired - Wed Oct 29, 8:02AM CDT
Allergan Canada, in partnership with ModiFace Inc., is delighted to announce the launch of the Juvederm(R) Visualizer 3D iPad application. For the first time, users can create a 3D image of the potential results of Juvederm(R) facial filler showing all angles of their face. This new application enables you to simulate the effects of Juvederm(R) facial filler by creating a 3D image of your face that can be rotated and viewed from all angles. You can then apply over 10 Juvederm(R) treatment effects such as smoothing laugh lines and enhancing cheeks and lips.
AGN: 190.06 (+0.62)
Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:00AM CDT
Gilead Sciences, Inc. reported third-quarter earnings (including stock-based compensation expenses) of $1.79 per share.
AGN: 190.06 (+0.62), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), ABBV: 63.46 (+2.28)
Pfizer Q3 Earnings Top Estimates Despite Generic Pressure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 3:10PM CDT
Pfizer's (PFE) third quarter earnings and revenues were better-than-expected despite the presence of generic pressure.
AGN: 190.06 (+0.62), BIIB: 321.08 (+0.08), PFE: 29.95 (+0.11), ABBV: 63.46 (+2.28)
Allergan (AGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Oct 28, 1:44PM CDT
The following Allergan (AGN) conference call took place on October 27, 2014, 09:00 AM ET. This is a transcript of that earnings call:
AGN: 190.06 (+0.62)
Stock Market News for October 28, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 9:10AM CDT
Benchmarks were little changed on Monday as investors took a breather following last week’s sharp gains
MU: 33.09 (+1.27), VRX: 133.04 (+1.53), NBR: 17.85 (+0.35), HAL: 55.14 (+1.22), XOM: 96.71 (+2.26), BRCD: 10.73 (+0.24), SLB: 98.66 (+1.04), AGN: 190.06 (+0.62), CHK: 22.18 (+0.83), MRK: 57.94 (+0.63), EOG: 95.05 (+2.83), DD: 69.15 (+1.49), PX: 125.99 (+3.32), CVX: 119.95 (+2.75), VZ: 50.25 (+0.35), DOW: 49.40 (+1.15), ECL: 111.23 (+2.88)
